文献速递神经免疫

用于识别AQP4-IgG阳性视神经脊髓炎谱系疾病疾病活动的血液生物标志物

Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项回顾性纵向多中心队列研究纳入181例AQP4-IgG阳性NMOSD患者共625份血清样本,确定sGFAP在攻击后1周内、sNfL在1至8周评估最佳, remission定义为攻击后至少6个月;sGFAP的z评分 cutoff 3.0和sNfL的2.1可区分攻击与缓解,并在德国和巴西队列验证。

要点

  • sGFAP在攻击后第一周内达峰,sNfL在攻击后5周达峰。
  • 评估攻击的最佳时间窗:sGFAP为1周内,sNfL为1至8周,缓解定义为攻击后至少6个月。
  • sGFAP的z评分cutoff 3.0和sNfL的2.1可区分攻击与缓解,验证队列中sGFAP敏感度和特异度均为100%。

核心结论

  • 该纵向队列研究建立了sGFAP和sNfL的最佳评估时机和阈值,并在独立队列中保持一致,支持这些生物标志物区分NMOSD攻击与缓解的有效性。

研究设计与样本

  • 回顾性、纵向、多中心队列研究,纳入AQP4-IgG阳性NMOSD且有储存血清样本的患者,共181例患者625份样本。
  • 发现队列样本采集于2008年2月至2023年10月,验证队列样本采集于2013年1月至2023年10月,两队列联合分析于2023年11月至2024年3月进行。
  • sNfL和sGFAP浓度采用单分子阵列法测定。

主要发现

  • 发现队列包括78例韩国患者的366份样本(中位[IQR]年龄35[30-42]岁;73例女性[95%]),验证队列包括34例德国患者的190份样本(中位[IQR]年龄54[39-61]岁;32例女性[94%])和69例巴西患者的69份样本(中位[IQR]年龄46[35-55]岁;62例女性[90%])。
  • 发现队列中74例患者的202份样本分析显示,攻击后6个月内sGFAP水平在第一周内达峰,sNfL水平在攻击后5周达峰。
  • sGFAP的z评分cutoff 3.0和sNfL的2.1可有效区分攻击期与缓解期,曲线下面积分别为0.95(95%CI,0.88-1.02)和0.87(95%CI,0.82-0.91)。
  • 将发现队列的时间窗和cutoff值应用于验证队列,德国和巴西队列中sNfL的敏感度为71%、特异度为94%,sGFAP的敏感度和特异度均为100%。

关键数值与推荐

  • 评估攻击的最佳时间窗:sGFAP为攻击后1周内,sNfL为攻击后1至8周。
  • 缓解定义为攻击后至少6个月。
  • 区分攻击与缓解的z评分cutoff:sGFAP为3.0,sNfL为2.1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The temporal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) as biomarkers of disease activity for neuromyelitis optica spectrum disorder (NMOSD) remain underexplored. OBJECTIVE: To determine optimal timing for assessing sGFAP and sNfL, establish cutoff values differentiating between attacks and remissions in NMOSD, and evaluate these findings across independent cohorts. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, longitudinal, multicenter cohort study was conducted among patients with aquaporin-4 antibody (AQP4-IgG)-positive NMOSD. Patients with available stored serum samples were included, totaling 181 patients with 625 samples. Discovery cohort samples were collected from February 2008 to October 2023 and validation cohort samples were collected from January 2013 to October 2023. A combined analysis of both cohorts was conducted from November 2023 to March 2024. EXPOSURES: sNfL and sGFAP concentrations, measured by a single-molecule array assay. MAIN OUTCOMES AND MEASURES: The primary outcomes were the optimal timing of assessing sGFAP and sNfL and the adjusted cutoff values for evaluating disease activity in NMOSD. RESULTS: The discovery cohort consisted of 366 samples from 78 Korean patients (median [IQR] age, 35 [30-42] years; 73 female patients [95%]), while the validation cohort included 190 samples from 34 German patients (median [IQR] age, 54 [39-61] years; 32 female patients [94%]) and 69 samples from 69 Brazilian patients (median [IQR] age, 46 [35-55] years; 62 female patients [90%]). Six-month postattack temporal biomarker dynamics were analyzed in 202 samples from 74 patients in the discovery cohort: sGFAP levels peaked within the first week and sNfL levels peaked at 5 weeks postattack. The optimal time frames for evaluating attacks were within 1 week for sGFAP and from 1 to 8 weeks for sNfL, with remission defined as at least 6 months postattack. z Score cutoffs of 3.0 for sGFAP and 2.1 for sNfL effectively distinguished between attack and remission phases, indicated by area under the curve values of 0.95 (95% CI, 0.88-1.02) and 0.87 (95% CI, 0.82-0.91), respectively. The discovery cohort time frames and cutoff values were applied to the validation cohort, achieving 71% sensitivity and 94% specificity for sNfL and 100% sensitivity and specificity for sGFAP in the German and Brazilian cohorts. CONCLUSIONS AND RELEVANCE: This longitudinal cohort study established optimal timing and thresholds for sGFAP and sNfL, which were consistent in independent cohorts, supporting these biomarkers' effectiveness in distinguishing NMOSD attacks from remission.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Kim SH, Gomes ABAGR, Schindler P, et al. Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2025. PMID: 39714824. doi:10.1001/jamaneurol.2024.4400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。